162 related articles for article (PubMed ID: 37857563)
21. Prognostic Value and Immune-Infiltration Pattern of
Yang Z; Shen X; Luo S; Li Y
Dis Markers; 2022; 2022():9621701. PubMed ID: 35126794
[TBL] [Abstract][Full Text] [Related]
22. Identification of a metabolism-related gene expression prognostic model in endometrial carcinoma patients.
Jiang P; Sun W; Shen N; Huang X; Fu S
BMC Cancer; 2020 Sep; 20(1):864. PubMed ID: 32894095
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.
Ma H; Feng PH; Yu SN; Lu ZH; Yu Q; Chen J
BMC Cancer; 2022 May; 22(1):543. PubMed ID: 35562682
[TBL] [Abstract][Full Text] [Related]
25. Immune-Related Gene-Based Novel Subtypes to Establish a Model Predicting the Risk of Prostate Cancer.
Zhang E; He J; Zhang H; Shan L; Wu H; Zhang M; Song Y
Front Genet; 2020; 11():595657. PubMed ID: 33281882
[TBL] [Abstract][Full Text] [Related]
26. Prognostic evaluation of the novel blueprint of DNA methylation sites by integrating bulk RNA-sequencing and methylation modification data in endometrial cancer.
Zhou H; Zhang Y; Jin J; Shen K; Yang Y; Lao P
J Gene Med; 2024 Jan; 26(1):e3638. PubMed ID: 38011892
[TBL] [Abstract][Full Text] [Related]
27. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
28. Analysis of Tumor Microenvironment Heterogeneity among Breast Cancer Subtypes to Identify Subtype-Specific Signatures.
Li J; Wu J; Han J
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672784
[TBL] [Abstract][Full Text] [Related]
29. Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer.
Shi R; Li H; Wei S; Yu Z; Zhang J; Zhang Q; Zhou T; Yao Y; Zhang Q; Zhang T; Wang H
BMC Cancer; 2023 May; 23(1):491. PubMed ID: 37259038
[TBL] [Abstract][Full Text] [Related]
30. Significance of
Chen Y; Zhao W; Bi F; Pan X; Yin L; Zhao C
Oxid Med Cell Longev; 2022; 2022():1817339. PubMed ID: 35847579
[TBL] [Abstract][Full Text] [Related]
31. Development and implementation of a prognostic model for clear cell renal cell carcinoma based on heterogeneous TLR4 expression.
Zhou Q; Sun Q; Shen Q; Li X; Qian J
Heliyon; 2024 Feb; 10(4):e25571. PubMed ID: 38380017
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
33. Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer.
Shu W; Wang Z; Zhang W; Zhang J; Zhao R; Yu Z; Dong K; Wang H
Comb Chem High Throughput Screen; 2023; 26(8):1488-1502. PubMed ID: 36200154
[TBL] [Abstract][Full Text] [Related]
34. Biomarker-driven therapy in endometrial cancer.
Karpel H; Slomovitz B; Coleman RL; Pothuri B
Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
[TBL] [Abstract][Full Text] [Related]
35. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Bonazzi VF; Kondrashova O; Smith D; Nones K; Sengal AT; Ju R; Packer LM; Koufariotis LT; Kazakoff SH; Davidson AL; Ramarao-Milne P; Lakis V; Newell F; Rogers R; Davies C; Nicklin J; Garrett A; Chetty N; Perrin L; Pearson JV; Patch AM; Waddell N; Pollock PM
Genome Med; 2022 Jan; 14(1):3. PubMed ID: 35012638
[TBL] [Abstract][Full Text] [Related]
36. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.
Talhouk A; Derocher H; Schmidt P; Leung S; Milne K; Gilks CB; Anglesio MS; Nelson BH; McAlpine JN
Clin Cancer Res; 2019 Apr; 25(8):2537-2548. PubMed ID: 30523022
[TBL] [Abstract][Full Text] [Related]
37. An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients.
Tang S; Zhuge Y
Biomed Eng Online; 2021 Jun; 20(1):64. PubMed ID: 34193185
[TBL] [Abstract][Full Text] [Related]
38. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods.
Bayramoglu D; Seçilmiş Kerimoğlu Ö; Bayramoğlu Z; Çintesun E; Şahin G; Karabağlı P; Çelik Ç
Ginekol Pol; 2023; 94(1):3-11. PubMed ID: 35072228
[TBL] [Abstract][Full Text] [Related]
39. Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.
Wu H; Zhang J
Gynecol Oncol; 2018 Jun; 149(3):592-597. PubMed ID: 29602546
[TBL] [Abstract][Full Text] [Related]
40. Autophagy-related risk signature based on CDNK2A to facilitate survival prediction of patients with endometrial cancer.
Yue C; Lin B; Sun X; Xu X; Zhou C; Fan J
J Gene Med; 2024 Jan; 26(1):e3648. PubMed ID: 38282156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
